R&D Pipeline

Aptamer Technology Disease Indication Lead-Op Pre-Clin Dev Phase 1 Phase 2 Phase 3
BT200 VWD type 2B
BT200 Hemophilia A: non-severe
BT200 VWD type 3
BT200 VWD type 1
BT200 Hemophilia A: severe
Anti-IL-23 Dermatology
Anti-IL-23 Gastroenterology
Anti-Her3 Oncology
Anti-GPC3 Oncology
Anti-LRRC15 Oncology


© 2023 Guardian Therapeutics. All rights reserved.

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:

Business Development Inquiries: businessdevelopment@guardian-rx.com